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Ras-GTPase-activating proteins (Ras-GAPs) have been implicated both as 
suppressors of Ras and as effectors in regulating cellular activities.  To study 
whether Ras-GAPs have roles in tumor cell survival or not, mRNA levels of 
ras-related genes were measured in v-Ki-ras-transformed (DT) and the parental 
NIH/3T3 cells, using real-time PCR.  mRNA levels of p120-Gap, Gap1m, and 
PIK3CA were increased in DT cells compared with NIH/3T3 cells.  p120-Gap and 
PIK3CA genes were induced by addition of serum or epidermal growth factor to 
serum-starved DT cells.  Three anticancer drugs, an ERK kinase (MEK) inhibitor 
PD98059, a topoisomerase II poison doxorubicin (adriamycin), and a histone 
deacetylase inhibitor trichostatin A, selectively blocked the overexpression of 
p120-Gap and Gap1m genes in DT cells.  These drugs also caused reversion of DT 
cells to the adherent shape associated with growth arrest.  Our results suggest that 
p120-Gap and Gap1m genes provide important biomarkers for cancer therapies. 
 











Ras proteins (Ki-, Ha-, and N-Ras) are three closely related members of the Ras 
family, which controls various cellular processes, such as growth and proliferation [1].  
Oncogenic mutants of ras genes are found in about 30 % of human tumors.  Especially, 
pancreatic adenocarcinoma is the tumor with the highest incidence of Ki-ras point 
mutations, occuring in 70 to 90% of all cases [2]. 
Ras cycles between a GTP-bound form (Ras-GTP) and a GDP-bound form (Ras-GDP).  
The active Ras-GTP is converted to the inactive Ras-GDP by intrinsic GTPase activity, 
which is accelerated by the GTPase-activating protein (Ras-GAP) [1].  Oncogenic Ras is 
associated with Ras-GAP [3], where it is insensitive to catalysis by GAP [4].  Therefore, 
oncogenic Ras always remains in the GTP-bound form, which cannot switch off the 
downstream signal.   
Several types of GAP proteins for Ras have been identified in mammalian cells, 
including p120-GAP, neurofibromin (the product of Nf1 tumor-suppressor gene) and 
GAP1 [5].  The classical Ras-GAP, p120-GAP, has two Src-homology (SH)2 and one 
SH3 domains.  SH domains of p120-GAP function as effectors by associating with 
several tyrosine-phosphorylated proteins [5], which induce Ras-dependent gene expression 
[6] and repress adhesion [7].  In addition, p120-GAP is involved in Ras transformation [8, 
9], cell survival [10, 11, 12] tumor cell invasion [13], and v-Src-induced cytoskeletal 
disruption [14].  Based on these findings, p120-GAP proteins show promise as a target 
for anticancer approaches [11].  However, it is still not clear that p120-GAP contributes to 
the tumor cell activity, since full Ras function requires multiple downstream pathways, i.e. 
cascades from Raf to extracellular signal-regulated kinase (ERK), from p120-GAP to p190 
Rho-GAP, and from phosphatidylinositol 3-kinase (PI3K) to AKT [1]. 
The 100 kDa Ras-GAP1 family contains two closely related proteins, GAP1m [15] 
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and GAP1IP4BP [16] / GAPIII (a mouse homologue of GAP1IP4BP) [17].  Though roles 
of GAP1 are not completely clear, its distinct perinuclear localization [18] leads us to 
expect that GAP1m might be involved in the transcriptional process.  Physiologically, 
GAP1 has the G protein (Gα12)- [19] and inositol 1,3,4,5-tetrakisphosphate 
(Ins(1,3,4,5)P4)-binding sites [20], and activates inositol tetrakisphosphate (IP4)-gated 
Ca2+ influx [21].  The same line of evidence is provided by us that bradykinin and 
Ins(1,3,4,5)P4 induce continuous Ca
2+ influx in oncogenic ras-transformed NIH/3T3 
fibroblast DT cells [22], predicting the up-regulated GAP1 function [23, 24].   
To know whether Ras-Gap gene expressions are up-regulated and linked to the tumor 
biological activity in ras-tranformed cells, we compared mRNA expressions of four 
ras-Gap genes (p120-Gap, Gap1m, GapIII, Nf1) between DT [25] and parental NIH/3T3 
cells, and studied their sensitivity to anti-cancer drugs.  We also measured the viral 
oncogene v-Ki-ras, PIK3CA which encodes the p110α catalytic subunit of PI3K [1], p53 
that encodes a transcription factor which induces cellular senescence in response to 
oncogenic Ras signals [26], and PTEN tumor suppressor gene that encodes a phosphatase 
[27] which inhibits ras transformation in NIH/3T3 cells [28].   
 
 
Materials and methods 
Cell culture.  v-Ki-ras-transformed NIH/3T3 fibroblasts (DT) [25] and parental 
mouse NIH/3T3 cells were grown in Dulbecco`s modified Eagle`s medium (DMEM), 
supplemented with 10% (v/v) fetal calf serum (FCS).  v-Ha-ras-transformed rat 
fibroblasts (tet-H-ras/CREF: tet-off) and parental cells (tet-H-ras/CREF: tet-on) [29] were 
grown as the above condition.  2 x 105 cells (trasformants) or 3-5 x 105 cells (parental 
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cells) were seeded in 100-mm dishes and grown for 2 days to meet the exponentially 
proliferating phase.  
RNA isolation and cDNA purification.  Total RNA from cells at the exponential 
phase was isolated by RNA-zol, and further treated with RNase-free DNase I.  Absence 
of contaminating genomic DNA in RNA samples was verified by QRT-PCR up to 40 
cycles using β-actin primers.  Reverse transcription reactions were performed by 5 μg of 
total RNA in 20 μl of DNase-, RNase-free water with murine reverse transcriptase and 
random hexadeoxynucleotides, using a first-strand cDNA synthesis kit.  
Real-time quantitative reverse transcription-PCR (QRT-PCR).  Primers were 
designed to amplify segments of <150 bp to maximize efficiency, which are summarized 
in Table 1.  Expressions of the above genes were determined by QRT-PCR using the ABI 
PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA).  
PCR reaction was performed with SYBR Green, the double-strand DNA-selective 
fluorescent dye.  25-μl of reaction mixture was composed of 12.5 μl of 2X SYBR Green 
PCR Master Mix, 500 nmol/l forward primer, 500 nmol/l reverse primer and 1.1 ng of 
first-strand cDNA.  Data were analyzed using GeneAmp 7700 sequence detection system 
(SDS) software (version 1.6.3) and converted into threshold cycle (Ct) values.  
Expression of the housekeeping gene, β-actin, was used to normalize for variances in input 
cDNA.  To adjust for variations in the amount of input cDNA, a Ct value for each gene 
was normalized against the Ct value for the housekeeping gene, i.e., ΔCt=Ct (specific 
gene) – Ct (β-actin).  A linear standard curve representing 4-fold dilutions of DT stock 
cDNA (1:2.5, 1:10, 1:40, 1:160) versus ΔCt was used for evaluating gene expression of 
unknown samples.  All experiments were performed in triplicate and repeated 2 times.  
The PCR products were also examined using 2% agarose gel electrophoresis.  After 
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ethidium bromide staining, bands were visible only at the expected molecular weights for 
each target mRNA product. 
Western blot.  Cells were treated with SDS buffer including 0.2% β-mercaptoethanol.  
15 μg of the samples for each lane was analyzed on a 10% SDS-PAGE followed by 
blotting on a nitrocellulose membrane.  The membrane was incubated with antibodies, 
and subsequently visualized using the chemiluminescent solution.  The visualized signals 
was analyzed by J-image software. 
Cell count.  Viable cell numbers were determined by trypan blue dye exclusion 
counted in a Neubauer-type hemocytometer.  All experiments were performed in 
duplicate and repeated 3 times. 
Sources of Drugs.  EGF, doxorubicin and monoclonal anti-β-actin antibodies were 
purchased from Sigma (St. Louis, Mo., USA).  PD98059 was purchased from BIOMOL 
Research Laboratories (Plymouth Meeting, PA, USA) or CALBIOCHEM (San Diego, CA, 
USA).  TSA was obtained from Wako Pure Chemicals (Osaka, Japan).  RNA-zol was 
obtained from BIOTECH LAB (Houston, TX, USA), and DNase I from Takara 
biomedicals (Otsu, Japan).  The first-strand cDNA synthesis kit was purchased from 
Amersham Pharmacia Biotech (Buckinghamshire, UK).  SYBR Green Master Mix was 
obtained from Applied Biosystems (Foster City, CA, USA).  Primers were synthesized at 
Hokkaido System Science (Sapporo, Japan).  Mouse monoclonal antibodies against 
human Ras-GAP was obtained from BD Biosciences Pharmingen (San Diego, CA, USA).  
Goat anti-mouse IgG antibodies and chemiluminescent solution were obtained from Pierce 




Results and Discussion 
p120-Gap, Gap1m and PIK3CA overexpression in DT cells 
In this study we investigated the biological activity of oncogenic v-Ki-ras transformed 
clone (DT cells) by measuring mRNA levels of ras-related genes.  Fig. 1A shows 
comparative mRNA expression analysis of DT cells versus parental NIH/3T3 cells.  
p120-Gap and Gap1m mRNA expressions were higher in DT cells by 9.3-fold and 
12.2-fold over the parental cells, respectively (mean value).  PIK3CA expression was also 
higher by 6.2-fold.  mRNA expressions of other target genes, GapIII, Nf-1, PTEN and 
p53, were at the similar levels between DT and NIH/3T3 cells.  p120-GAP protein 
expressions were also increased in DT cells by 2.6-fold (Fig. 1B).   
We also tested mRNA levels of ras-Gap genes in the different cells.  In another 
v-Ki-ras transformant, 635 cells, p120-Gap and Gap1m expressions were higher by 
2.1-fold and 4.2-fold over the parental NIH/3T3 cells, respectively.  Similarly, in 
v-Ha-ras-transformed fibroblasts with the regulatable Ha-ras(V12) gene (tet-H-ras/CREF) 
[29], p120-Gap and Gap1m expressions were also higher over the parental (ras off) cells 
by 3.5-fold and 3.5-fold, respectively (data not shown).  These results indicate that 
transformation of ras may cause increase in mRNA levels of p120-Gap and Gap1m, 
though the extent is variable.  The different expression levels might be related to the 
tumor biological activity, as the doubling time in DT cells (10.3 hrs in the present study) is 
shorter than that in 635 cells (20 hrs) or tet-H-ras/CREF cells (18.6 hrs).  
Our results are in accord with the role of PIK3CA implicated as an oncogene in 
ovarian cancer [30].  Besides our results are novel in that p120-Gap and Gap1m genes are 
involved in ras-transformation.  Therefore, it could be predicted that the up-regulated 
ras-Gap genes as well as PIK3CA facilitate DT cell survival.  
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Next, we studied effects of growth factors on gene expressions.  2 hrs after 
stimulation of DT cells with 10 % FCS or EGF (25 ng/ml), p120-Gap expression was 
increased by 8.0- and 5.0-fold of the serum-starved level, respectively (Fig. 2A-a and -c).  
PIK3CA expression was also strongly induced after stimulation with growth factors.  
Gap1m expression was slightly induced after stimulation with FCS and EGF by 3.3-fold 
and 2.9-fold, respectively.  On the other hand, apparent changes of GapIII and Nf-1 
expressions were not detected either by FCS or EGF in this study (Fig. 2A-a).  As shown 
in Fig. 2A-b and -d, neither FCS nor EGF affected the steady-state mRNA levels of all 
tested genes in parental NIH/3T3 cells.  These results indicate that mRNA induction of 
p120-Gap, Gap1m and PIK3CA genes is growth factors-dependent in 
v-Ki-ras-transformed DT cells.  Similar results were observed in the v-Ha-ras 
transformants: 2 hrs of serum-deprivation resulted in decrement of p120-Gap expression 
by -8.2-fold, and subsequent addition of EGF caused increment by 3.8-fold (Fig. 2B-a).   
   
PD98059 selectively reduces p120-Gap and Gap1m mRNA expressions in DT cells 
To determine whether these overexpressed genes are positively or negatively involved 
in DT cell survival, effects of several anti-cancer drugs on gene transcription were studied.  
Treatment of DT cells with the specific MEK inhibitor PD98059 (50 μM) for 48 hrs 
selectively decreased the expression levels of p120-Gap and Gap1m mRNA to –9.6-fold 
and –12.3-fold, respectively (Fig. 3A-a).  6 other genes stayed at almost the same level.  
PD98059 did not affect the steady-state mRNA levels of all target genes in NIH/3T3 cells 
(Fig. 3A-b).  We also performed a time course analysis of mRNA levels of p120-Gap and 
Gap1m genes in PD-treated DT cells.  PD98059 caused rapid decreases during the initial 
4 hrs in the expression of both p120-Gap and Gap1m, followed by gradual decreases 
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during the next 5 - 24 hrs (data not shown).  The result suggests that expressions of 
p120-Gap and Gap1m are regulated by factor(s) downstream of MEK.  A plausible one is 
the activator protein-1 (AP-1) transcription factor, such as cJun and Fra1 [31].   
 
Blocking overexpression of ras-Gap genes by doxorubucin in DT cells 
To determine whether common chemotherapeutic agents affect target gene 
transcription in DT cells, we focused on the topoisomerase II (topo II) poison, doxorubicin 
(adriamycin).  Doxorubicin (10 μM) treatment for 4 hrs caused selective reduction in 
Gap1m expression to –5.1-fold among 8 genes tested in DT cells (Fig. 3B-a).  
Suppression of Gap1m expression after 4 hrs of treatment was prior to apparent growth 
arrest or apoptosis (Fig. 4B).  Doxorubicin did not affect the steady-state mRNA levels of 
all target genes in NIH/3T3 cells (Fig. 3B-b).  Time course analysis shows that p120-Gap 
expression level was also reduced to –6.5-fold after 12 hrs of doxorubicin treatment (Fig. 
4A-a).  After 24 hrs of treatment, p120-Gap and Gap1m expressions were equally 
reduced (–9.9 and –9.6-fold).  In contrast to this, Expressions of 6 other genes were less 
modulated until after 12 hrs of treatment (Fig. 4A).  Thus, doxorubicin treatment 
down-regulated overexpression of p120-Gap and Gap1m genes in DT cells.  These 
results implicate that the reduced ras-Gap mRNA levels contribute to the growth 
inhibitory properties of doxorubicin.  For a mechanism of down-regulation of ras-Gap 
genes, the topo II poison doxorubicin might suppress the expression of immediate early 
genes.  A plausible target is the AP-1, since AP-1 activity reflects the tumor sensitivity to 
doxorubicin [32].   
   
Effect of trichostatin A on ras-Gap and p53 mRNA expressions in DT cells 
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Histone deacetylase (HDAC) inhibitors induce morphological reversion in various 
tumors [33], thus hold promise as anticancer agents.  We studied whether trichostatin A 
(TSA), a specific HDAC inhibitor, regulates the transcription of ras-related genes in DT 
cells.  TSA (100 ng/ml) treatment for 12 hrs reduced p120-Gap, Gap1m and p53 
expressions of DT cells to –5.3, –4.6, and –12-fold of the pre-treated level, respectively 
(Fig. 3B-a).  It did not affect the steady-state mRNA levels of all target genes in NIH/3T3 
cells, with the exception of p53 (–13-fold) (Fig. 3B-b).  We found a rapid suppression 
with a partial recovery of p120-Gap expression, –9.3-fold for 4 hrs and –5.0-fold for 24 
hrs of treatment (data not shown).   
 
Effects of PD98059, doxorubicin and TSA on morphology and growth in DT cells. 
Finally, in order to understand the biological effects of ras-Gap mRNA overexpression, 
we studied the modulation of cell morphology and growth by above agents (Fig. 3D).  
After 24 hrs of treatment with PD98059 (50 μM), DT cells of round, thick and 
non-adherent shapes were altered to be long, flat and adherent shapes, more similar to 
those of NIH/3T3 cells.  After 24 hrs of treatment with doxorubicin (10 μM), survived 
cells were converted to a flat and adherent shape.  TSA (100 ng/ml) treatment for 24 hrs 
also induced adherent shape in DT cells, as reported previously [33].  The number of DT 
cells treated with PD, doxorubicin, TSA for 24 hrs was reduced to 39 ± 13 %, 12 ± 3 %, 23 
± 12 % of untreated DT cells (n=6), respectively.  Thus, treatment with these drugs 
caused growth arrest and morphological reversion of DT cells to adherent and flat shapes.  
As p120 Ras-GAP suppresses focal adhesion by its association with p190 Rho-GAP [7], 
our results suggest that the up-regulated p120-Gap causes repression of Rho signaling, 
leading to the decreased focal adhesion, thereby increases motility in DT cells. 
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We focused on two sets of information by profiling of mRNA expression in this study.  
One is the causal information for tumorigenesis, as discussed above.  Another is to find 
biomarkers for the new molecular specific therapy.  Our results indicate that p120-Gap 
and Gap1m are included in important biomarkers for evaluating the biological activity, and 
for anti-cancer treatments in some of ras-mutated tumors.   
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Fig. 1.  Monitoring of expression in v-Ki-ras-transformed and control mouse 
fibroblasts. 
(A-a) The relative expression level of 7 genes was determined in RNA samples from 
v-Ki-ras-transformed DT and parental NIH/3T3 cells using real-time quantitative PCR.  
Housekeeping normalized units (Δthreshold cycle) for each gene obtained in the PCR 
analysis were used to determine the fold-change among samples.  Bars represent 
fold-changes of the mRNA level of particular genes when comparing DT with parental 
NIH/3T3 cells.  Positive values indicate that the transcript is more abundant in DT than 
NIH/3T3 cells (overexpressed), and negative values indicate the opposite (underexpressed).  
Data are expressed as the mean  ± S.D., performed in duplicate and repeated 2 times.  
(A-b, c) Each plot represents the baseline-subtracted fluorescence intensity (ΔRn) that 
reflects mRNA levels of p120-Gap (b), Gap1m (c), or β-actin genes.  Horizontal lines 
indicate threshold lines set in the exponentially increasing area calculated by SDS software.  
(B) Comparison of Ras-GAP expression pattern by immunobloting in DT cells and 
parental NIH/3T3 cells.  The top bands marked by the arrow indicate full-length (115 
kDa) p120 Ras-GAP proteins. 
 
Fig. 2.  Genes induced in response to fetal calf serum (FCS) or epidermal growth 
factor (EGF) in DT and NIH/3T3 cells.   
(A-a, b) DT cells (a) and NIH/3T3 cells (b) were serum-starved for 2 hrs (pre), followed 
by treatment with 10% FCS (shaded bars) or EGF (25 ng/ml) (hatched bars) for 2 hrs 
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(post).  Bars represent fold-changes of the mRNA level of 8 genes when comparing the 
stimulated cells (post) with serum-starved control cells (pre).  Data are expressed as the 
mean ± S.D. performed in duplicate and repeated 2 times.  (A-c, d) Representative 
amplification plots for p120-Gap and β-actin. (B) v-Ha-ras-transformed (tet-H-ras/CREF: 
tet-off) and parental (tet-H-ras/CREF: tet-on) cells originally in 10 % FCS condition were 
serum-starved for 2 hrs, followed by addition of EGF (25 ng/ml) for 2 hrs. 
 
Fig. 3.  Effects of PD98059, doxorubicin and trichostatin A on mRNA levels of 
ras-related genes and the cell morphology in DT and parental cells 
(A-C) Treatment with 50 μM PD98059 for 48 hrs (A), 10 μM doxorubicin for 4 hrs (B), 
100 ng/ml trichostatin A for 12 hrs (C) in DT (a) and NIH/3T3 (b) cells.  Bars represent 
fold-changes of the mRNA level of 8 genes when comparing drug-treated cells with 
untreated cells.  Data are expressed as the mean ± S.D.  (D) Phase contrast images of DT, 
NIH/3T3, DT cells treated for 24 hrs with 50 μM PD98059, 10 μM doxorubicin, or 100 
ng/ml trichostatin A. 
 
Fig. 4.  mRNA expression levels of ras-related genes in doxorubicin-treated DT cells.  
(A) Each plot represents the fold-change of the mRNA level of 8 particular genes (a-c) 
when comparing DT cells treated with 10 μM doxorubicin for indicated periods with 
untreated cells.  Each symbol represents the mean ± S.D.  (B) Effects of doxorubicin on 
the DT cell growth.  Each plot represents the fold-change of cell numbers when 
comparing DT cells treated with 10 μM doxorubicin (●) with untreated cells (○).  Each 
symbol represents the mean ± S.D.  
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Table 1.  Primer sequences for real-time QRT-PCR 
                                 
m-p120-Gap  F:  5`-CGTGGTGTACAGCAGCATGTACT-3` 
    R:  5`-AGGCTGCTACCTGATGTCA-3` 
 
m-Gap1m 5`-AGTTCACCATTGAGGATTCT-3`  
  5`-CTCATGAGGTTCATCGAGCTT-3` 
 
m-GapIII  5`-CTGAGACTGAGTGAGGTCATT-3` 
  5`-GAGACCCTGGCACTCGAAGAT-3` 
 
m-Nf-1   5`-GCAGGAGAACCTCTGCCTGACA-3` 
  5`-CATACACAGGACAGGAGCAAGT-3` 
 
m-PIK3CA 5`-GGCTCTGGAATGCCAGAACTA-3` 
    5`-CCACCATGATGTGCATCATTCAT-3`  
 
m-PTEN  5`-GGCTAGCAGTTCAACTTCTGTGACT-3` 
  5`-GGATCAGAGTCAGTGGTGTCAGA-3`  
 
m-p53     5`-TCACCTCACTGCATGGACGATCT-3`  
    5`-TGTGCTGCAGGAGCTCCTGACA-3` 
 
m-v-Ki-ras  5`-ACTTGTGGTAGTTGGAGCTA-3`  
    5`-GGAGTCCTCTATCGTAGGATCA-3`  
 
m-c-Ki-ras  5`-CACTTCCAGCATGTCCTAGA-3`  
    5`-CTAGCAGTGGAAAGCTAGA-3` 
 
m-β-actin  5`-CTCTAGGCACCAAGGTGTGAT-3` 
    5`-GGTACTTCAGGGTCAGGATA-3` 
 
r-p120-Gap  5`-GTTGCACCACCAGAGCCAGTA-3` 
    5`-CAGAATGGCTCGTACACGTCTT-3` 
 
r- Gap1m  5`-GTACGACTGTTGCTGCATCACA-3` 
    5`-GTCAGCCACCGCAGTGATAA-3`  
 
r-β-actin   5`-TGGCTCCTAGCACCATGAAGATCA-3` 
    5`-GGACAGTGAGGCCAGGATAGA-3` 
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